@inproceedings{inproceedings, title = {{2-year open-label extension phase results from the pivotal phase 3 study of denosumab in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with denosumab or zoledronic acid}}, url = {{}}, year = {{2013}}, month = {{4}}, author = {{Kueppers F and Fizazi K and Brown J and Carducci M and Shore N and Sieber P and Karsh L and Wei R and Goessl C}}, volume = {{111}}, journal = {{BJU INTERNATIONAL}}, pages = {{91-92}}, note = {{Accessed on 2025/04/17}}}